← All Alnylam Pharmaceuticals, INC filings

Alnylam Pharmaceuticals, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
ALNY
Alnylam Pharmaceuticals, INC
10-K: Alnylam Achieves First Profitability, Driven by AMVUTTRA Growth
Alnylam Pharmaceuticals reports its first profitable fiscal year in 2025, fueled by robust sales of AMVUTTRA and strategic pipeline advancements.
NASDAQ
ALNY
Alnylam Pharmaceuticals, INC
10-K: Alnylam Pharmaceuticals Reports Progress on RNAi Therapeutics in 2024, Eyes Self-Sustainability by 2025
Alnylam Pharmaceuticals highlights advancements in its RNAi therapeutics pipeline and commercial performance in its 2024 annual report, aiming for self-sustainability by the end of 2025.
NASDAQ
ALNY
Alnylam Pharmaceuticals, INC
10-K: Alnylam Pharmaceuticals 2023 10-K Filing: Strategic Growth and Pipeline Progress
Alnylam Pharmaceuticals' 2023 10-K filing highlights its transition to a top-tier biotech company, marked by revenue growth, pipeline advancements, and strategic collaborations.